Small
stocks making big moves on Wednesday, November 19, 2014 (as of 4 pm EST), as
reported by Sean Mason, SmallCapPower.com
Cynapsus Therapeutics Inc. (TSXV: CTH)
shares shot up 17% to $1.03 on volume of more than 2.6 million shares Wednesday
after the specialty pharmaceutical firm focused on Parkinson’s disease reported
what it called “positive top-line results” from its CTH-105 Phase 2 clinical
trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s
disease.
As well,
shares of IAMGOLD Corp (TSX: IMG)
slipped 10% to $2.49 after the gold miner’s stock was downgraded
by Macquarie to ‘underperform’ from ‘neutral’ and its price target reduced
to $3.25 from $4.50.
VANC Pharmaceuticals Inc. (TSXV: NPH),
meanwhile, said it has received Natural Product Number approvals from Health
Canada to manufacture, market and sell four of its products immediately. VANC
Pharmaceuticals stock dropped 10% to $0.18 following the announcement.
Finally, Knight Therapeutics Inc. (TSX: GUD)
shares rose 8% to $6.53 after the specialty pharmaceutical
company announced the sale of its Neglected Tropical Disease Priority
Review Voucher for treatment of patients with visceral, mucosal and cutaneous
leishmaniasis to Gilead Sciences, Inc. for US$125 million in cash.
